NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Tyligand Bioscience

Tyligand Bioscience

Private
ShanghaiHealthcare & Life Scienceshttps://www.tyligand.com.cn/

Last Round

IPO

Jan 29, 2026

Est. Valuation

$222.2M

Total Funding Raised

$74.61M

Company Overview

Tyligand Bioscience is a biotechnology company that focuses on the discovery and development of innovative small molecule therapeutics and antibody-drug conjugates for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

biotechnologyoncology therapeuticsantibody-drug conjugatesADCsmall molecule inhibitorKRAS G12D inhibitordrug discoverysolid tumor treatmentbiopharmaclinical-stage biotechprecision medicinedrug licensingtumor microenvironmentprocess development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tyligand Bioscience Comparables

Compare Tyligand Bioscience with similar companies based on industry and business-model similarity.

Tyligand Bioscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Kumquat Biosciences
83%
BridgeBio Oncology
83%
Jacobio Pharmaceuticals Group Co Ltd
81%

Tyligand Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOJan 29, 2026
Series BApr 1, 2024
Series A ExtensionNov 1, 2022
Series AApr 1, 2021
Pre SeedSep 1, 2018

Tyligand Bioscience Investors

Notable investors and investment history

Tyligand Bioscience investors
InvestorRounds
Ming BioventuresSeries A Extension
Medfine CapitalPre Seed
Yijing CapitalSeries A
险峰K2VCPre Seed
Lilly Asia VenturesSeries B
Hongli Innovation InvestmentSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2024

    $27M round led by Lilly Asia Ventures.

Tyligand Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Tyligand Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tyligand Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2018
Last FundingJan 29, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.